Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 4/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21614699 | 0.89 | HDAC1 (0.49) | HDAC1HDAC8HDAC6SSTR4F2 | |
| SCHEMBL21611921 | 0.86 | HDAC4 (0.35) | HDAC1HDAC8HDAC6GRIN1GRIN2B | |
| SCHEMBL30763505 | 0.82 | HDAC1 (0.41) | HDAC1HDAC8HDAC6SSTR4SOS1 | |
| SCHEMBL21611932 | 0.76 | F2 (0.37) | HDAC1HDAC8HDAC6SSTR4SOS1 | |
| SCHEMBL30017260 | 0.75 | SOS1 (0.42) | SSTR4SOS1F2GRIN1GRIN2B | |
| SCHEMBL30017271 | 0.74 | BRD4 (0.40) | SSTR4SOS1GRIN1GRIN2B | |
| SCHEMBL20177003 | 0.74 | HTR2C (0.42) | HDAC1HDAC8HDAC6SSTR4DGAT1 | |
| SCHEMBL29686229 | 0.74 | HTR2C (0.42) | HDAC1HDAC8HDAC6SSTR4DGAT1 | |
| SCHEMBL25523616 | 0.71 | SSTR4 (0.42) | HDAC1HDAC8HDAC6SSTR4DGAT1 | |
| SCHEMBL21614712 | 0.71 | CACNA1G (0.40) | HDAC1HDAC8HDAC6AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883387-B2 | PqsR inverse agonists | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2024-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11883387-B2 | PqsR inverse agonists | QRFPR, P2RY11, QARS1 | HDAC1 3152/4885HDAC8 3862/4885HDAC6 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.